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1 Drug description 
Generic/Brand name/ATC code:  
Brentuximab vedotin (SGN-35) / Adcetris® / L01XC12 
Developer/Company: 
Seattle Genetics: commercialisation rights in the US and Canada; 
Takeda Group: commercialisation rights in the rest of the world 
Description:  
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed against 
the tumour necrosis factor (TNF) receptor CD30 which is expressed on the 
surface of tumour cells in haematological malignancies including Hodgkin’s 
lymphoma (HL) and anaplastic large cell lymphoma (ALCL) [1]. Brentuxi-
mab vedotin has potential antineoplastic activity and consists of three com-
ponents: the chimeric immunoglobulin G1 mAb cAC10, which is specific for 
human CD30; the microtubule-disrupting agent monomethyl auristatin E 
(MMAE – a synthetic analogue of the marine natural product doastatin 10 
that inhibits tubulin polymerization); and a protease-cleavable covalent 
linker that attaches cAC10 to MMAE [1, 2]. Binding of the ADC to CD30 on 
the cell surface initiates internalisation of the ADC-CD30 complex. Within 
the cell, MMAW is released via proteolytic cleavage. Binding of MMAW to 
tubulin disrupts the microtubule network within the cell, induces cell cycle 
arrest and results in apoptotic death of the CD30-expressing tumour cells 
[3]. 
The recommended dose of brentuximab vedotin is 1.8mg/kg administered as 
an intravenous (i.v.) infusion over 30 minutes once every 3 weeks (= one cy-
cle). Duration of treatment is recommended for up to 16 cycles, disease pro-
gression or unacceptable toxicities [4]. 
2 Indication 
Brentuximab vedotin is indicated  
 for the treatment of relapsed or refractory Hodgkin’s lymphoma (HL) 
after failure of at least two prior multi-agent chemotherapy regimens 
in patients who are not candidates for stem cell transplantation  
 and for the treatment of relapsed systemic anaplastic large cell lym-
phoma (sALCL) after at least one prior multi-agent chemotherapy. 
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3 Current regulatory status 
In June 2011, Takeda announced that the European Medicines Agency 
(EMA) has accepted the marketing authorisation application of AdcetrisTM 
for the treatment of relapsed or refractory HL and relapsed or refractory 
sALCL for review [5]. Brentuximab vedotin has received orphan drug desig-
nation for the treatment of cutaneous T-cell lymphoma in January 2011 [6].  
In August 2011, the US Food and Drug Administration (FDA) approved 
brentuximab vedotin (Adcetris®) for the following two indications: 
 for the treatment of patients suffering from HL after failure of autolo-
gous stem cell transplantation (ASCT) or after failure of at least two 
prior multi-agent chemotherapy regimens in patients who are not 
ASCT candidates; 
 for the treatment of patients with sALCL after failure of at least one 
multi-agent chemotherapy regimen. 
Brentuximab vedotin was approved for both indications based on response 
rates assessed in two phase II single-arm trials [7]. Data presenting im-
provements in patient reported outcomes or survival with brentuximab ve-
dotin are not yet available [4, 7]. In January 2007, the FDA granted orphan 
drug designation for brentuximab vedotin for the treatment of patients with 
HL [8] and in March 2009, fast track designation for the same indication 
was given [9]. 
4 Burden of disease 
Lymphomas are a type of malignant haematological disorders characterised 
by malignant cells generally originating from the lymph nodes. Depending 
on the histology, type and stage of the disease, lymphomas can be curable. 
Overall lymphomas are divided in Hodgkin’s lymphoma (HL; or Morbus 
Hodgkin) and Non-Hodgkin’s lymphoma (NHL) based on the presence or 
absence of the Reed-Sternberg-Cells (RS cells) [10]. HL is characterised by 
the presence of RS cells which carry the antigen CD30 acting as an integral 
membrane glycoprotein at their surface in 98.4% of all HL cases [11]. 
 
Hodgkin’s Lymphoma 
HL accounts for approximately 30% of all lymphomas and presents with a 
bimodal age-specific incidence pattern: patients between 15-35 years and pa-
tients aged >55 years [7]. The incidence of HL is 3 per 100,000 inhabitants 
annually, with men generally more often affected than women [10]. 
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The aetiology of HL is generally unknown. Because of presence of the Ep-
stein-Barr-Virus (EBV) DNA in the RS cells (40% in industrialised coun-
tries and 90% in developing countries), infections with the EBV are associ-
ated to play an important role for the development of HL [10]. At time of di-
agnosis >90% of patients present with a painless enlargement of lymph 
nodes, spleen or other immune tissues and with B-symptoms (fever >38°C, 
unexplained weight loss >10% of body weight within 6 months and night 
sweat). Other symptoms that might be present at diagnosis in 2-10% of HL 
cases are pruritus, fatigue, appetite loss and painful lymph nodes induced by 
alcohol [7, 10]. 
Overall, HL is considered to be a highly curable disease with a median 5-
year survival rate of >90% [12]. Despite good initial responses to therapy 
about 10-15% of patients with early stage disease and about 40% of patients 
with advanced-stage disease will relapse [11, 13]. 
About >85% of HL patients achieve long-term remissions (>90% in the lo-
calized and 70 - 80% in the advanced stages of the disease [12, 14]). Patients 
not achieving a remission or relapsing after initial therapy are eligible for 
high-dose chemotherapy with subsequent autologous hematopoietic stem 
cell transplantation (ASCT). About 30% of these patients then achieve long 
term remission [10] and up to 40% of patients that received ASCT will re-
lapse [7]. Patients in late relapse which are re-treated with chemotherapy 
achieve long-term disease-free survival in 50% of cases [14, 15]. 
Based on the Ann Arbor staging classification for Hodgkin and non-
Hodgkin lymphomas, four disease stages (stage I, II, III and IV) can be dis-
tinguished. Additionally, different sub-classifications are added to describe 
the characteristics of the disease in more detail. For example the letters A 
and B are added to the stage for the absence (A) or presence (B) of B symp-
toms [16, 17], the letter X is added when the bulk is >10 cm and E indicat-
ing extra-nodal disease [18]. Patients suffering from HL are usually classi-
fied in the following three groups: early stage favourable disease (stage I and 
II with no unfavourable factors), early stage unfavourable disease (stage I 
and II with any unfavourable factor such as large mediastinal adenopathy, B 
symptoms, numerous sites of disease, or significantly elevated erythrocyte 
sedimentation rate (ESR)), and advanced stage disease (stage III and IV) [7, 
19]. 
Unfavourable prognostic factors in early stage HL are mediastinal bulk, 
presence of B symptoms, >3 nodal sites of disease or an ESR of 50 or more 
[19]. In addition to that, seven unfavourable factors that reduce survival 
rates by 7% to 8% per year have been identified for advanced stage of HL: 
age ≥45 years, male gender, stage IV disease, albumin level below 4 g/dL, 
leucocytosis (white blood cell count more than 15,000/mm³), lymphocyto-
penia (lymphocyte count less than 8% of the white blood count and/or lym-
phocyte count less than 600/mm³) [19]. 
In 2009, 161 patients (79 men and 82 women) were newly diagnosed with 
HL in Austria [20]. Applying the above mentioned estimates, about 15 HL 
patients will require third-line therapy in Austria per year. 
 
widely unknown 
aetiology 
symptoms:  
painless enlargement of 
lymph nodes, spleen, B 
symptoms 
median 5-year survival: 
>90% 
high cure rate 
 
40% will relapse after 
HSCT 
Ann Arbor classification 
for the staging of HL 
unfavourable factors 
that reduce survival 
rates 
˜15HL pts require third-
line chemotherapy in 
Austria per year 
Horizon Scanning in Oncology 
6 LBI-HTA | 2012 
Systemic Anaplastic Large Cell Lymphoma (sALCL) 
Anaplastic large cell lymphomas (ALCL) are a rare, aggressive and hetero-
geneous type of non-Hodgkin’s Lymphoma (NHL). ALCL account for ap-
proximately 2-3% of all NHLs and for about 12% of all peripheral T-cell 
lymphomas (PTCL) [11, 21, 22]. The World Health Organisation’s (WHO) 
classification of haematopoietic tumours and lymphoid tissues breaks down 
ALCL into three sub-types: primary cutaneous (localized) ALCL and pri-
mary systemic (widespread) anaplastic lymphoma kinase (ALK-)positive 
ALCL and ALK-negative ALCL [21, 23, 24]. About 60% of ALCL patients 
present ALK-positive disease [24, 25]. Overall, ALCL has a considerable su-
perior survival compared to other PTCLs which is mainly driven by the im-
proved prognosis of ALK-positive patients compared to ALK-negative dis-
ease (5-year failure-free survival (FFS), 60% vs. 36%, p=0.015; and 5-year 
overall survival (OS), 70% vs. 49%, p=0.016, respectively) [23]. Response to 
initial ALCL therapy is usually of short duration and approximately 40-65% 
of patients will develop recurrent disease. A complete remission based on 
second-line therapy is achieved by approximately 25-30% of initially recur-
rent patients [26]. In ALK-positive ALCL median age at diagnosis is 35 
years and men are more often affected than women; the median age of pa-
tients at diagnosis in ALK-negative disease is 61 years with no gender pre-
dominance [21]. 
The majority (75%) of ALK-positive ALCL patients present with B symp-
toms and advanced stage of disease (stage III or IV) at time of diagnosis [21, 
24]. ALCL frequently involves both lymph nodes and extranodal sites (50-
80%). The most common extranodal site is skin (21-35%), followed by bone 
(17%), soft tissue (17%), lung (11%), bone marrow (10%) and liver (8%) 
[24]. 
In ALCL, the most important prognostic indicator is ALK positivity. Also 
the International Prognostic Index (IPI) is of prognostic relevance in ALCL, 
despite it is validated in patients with diffuse-large B-cell lymphoma and 
not an appropriate prognostic tool for T-cell lymphomas overall [24]. The 
IPI provides a prognostic score based on clinical and laboratory factors tak-
ing age, elevated serum LDH, performance status, stage of the disease (Ann 
Arbor staging) and extranodal involvement into account [25]. Depending on 
the amount of presenting risk factors four risk groups (low, low intermedi-
ate, high intermediate and high) are distinguished [27].  
In Austria, 1,125 patients (577 men and 548 women) were diagnosed with 
NHL in 2009 [28]. Applying the above mentioned estimates, there are about 
15 ALCL patients eligible for second-line therapy in Austria per year. 
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5 Current treatment 
Hodgkin’s lymphoma 
Overall, HL is considered to be a highly curable haematological malignancy 
due to a significant progress in the management of HL patients in the past 
few decades. As a result of the development major treatment considerations 
in newly diagnosed HL patients nowadays often relate to the long-term tox-
icity, especially for patients with early- or intermediate-stage disease [29]. 
Despite these advances, about 30-40% of patients with advanced stage of the 
disease will relapse or are refractory to primary treatment [9]. 
Initial therapy of HL typically consists of chemotherapy and/ or radiation 
therapy depending on the stage of the disease, patient’s age and presence of 
risk factors [14, 29]. After completion of initial therapy follow-up is essential 
in order to monitor late effects such as secondary malignancies (e.g. lung 
cancer, breast cancer), cardiovascular disease, hypothyroidism and fertility 
issues [19]. 
Patients who relapse on or who are refractory to first-line therapy will then 
receive multi-agent chemotherapy with subsequent ASCT [30].  
In order to reduce the tumour burden and to mobilize stem cells prior to 
high-dose chemotherapy and ASCT, the following salvage regimens are 
given: 
 DHAP – dexamethasone / high-dose ara-C / cisplatin 
 IGEV – ifosfamide / gemcitabine / vinorelbine / dexamethasone 
 ICE – ifosfamide / carboplatin / etoposide [30]. 
Subsets of patients e.g. low-risk patients relapsing after primary treatment 
with two cycles of chemotherapy followed by radiotherapy or patients with 
localized late relapse, can be successfully salvaged with a second more inten-
sive conventional therapy (i.e. BEACOPPescalated) or radiotherapy alone, 
respectively [30]. 
However, about 40-50% of these patients will relapse again and have a poor 
prognosis with a median survival of 2 years from time of relapse to post-
ASCT [9, 14, 31]. 
Patients who are resistant to chemotherapy are not considered candidates 
for ASCT [32]. For patients not being eligible for ASCT or who relapse fol-
lowing an ASCT, no EMA or FDA approved agent exists. In the absence of 
randomized controlled trials (RCTs) investigating the efficacy of therapeutic 
options in that setting, no specific recommendations for the care of these pa-
tients can be made and therefore, enrolment in a clinical trial is recom-
mended [9, 14, 19]. Novel agents such as small molecule inhibitors, antibod-
ies or immunotoxins as single agents or in combination with conventional 
chemotherapy play an increasingly important role in the palliative setting of 
HL treatment [30]. 
For now, the major goals for the treatment of patients who are refractory or 
relapse after ASCT range from palliation of symptoms in relatively young 
patients to near-complete eradication of lymphoma cells to enable durable 
remission [9]. 
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Systemic anaplastic large cell lymphoma 
Besides brentuximab vedotin, there are currently no FDA approved drugs 
specifically for systemic ALCL. The current standard of care for first-line 
treatment of ALK-positive ALCL is CHOP, a combination regimen of the 
four chemotherapeutic drugs cyclophosphamide, hydroxydaunorubicin, vin-
cristine and prednisone [26]. Generally, the prognosis in this group of pa-
tients is so good that transplants should only be considered at relapse [24, 
33]. ALK-negative ALCL is less well characterized than ALK-positive 
ALCL. Currently the management is the same as for ALK-positive ALCL 
but as outcomes are less favourable it is recommended that the standard 
management should become the same as that for PTCL not otherwise speci-
fied (PTCL-NOS) a subgroup of PTCLs [24]. Despite disappointing results 
with conventional chemotherapy including CHOP in these subgroups of 
PTCL patients, CHOP remains besides enrolment onto a clinical trial the 
most commonly used first-line treatment as to date no preferred or most ef-
fective treatment for non-ALK-positive PTCLs has been established [24]. 
Patients relapsing after first-line therapy should be treated with a platinum-
based therapy or enrolled onto a clinical trial. Further second-line therapy 
options are dependent on whether patients are eligible for stem cell trans-
plantation or not. Generally, only PTCL patients that relapse or are primary 
refractory and have chemo-sensitive disease are considered to be transplant 
candidates [24, 34].  
Second-line therapy options for chemo-resistant patients and thus being 
non-candidates for stem cell transplantation are alemtuzumab, bortezomib, 
brentuximab vedotin for nodal ALCL only (excluding cutaneous ALCL), 
denileukin diftitox, gemcitabine, pralatrexate, radiation therapy or ro-
midepsin [27]. At this point it has to be mentioned that, whereas pra-
latrexate was approved for the treatment of relapsed or refractory PTCL by 
the US FDA in 2009, the EMA refused approval in 2012 for this indication 
due to concerns whether the benefits of pralatrexate could outweigh its risks 
[35] and is thus not available in Europe. Romidepsin for the treatment of re-
lapsed or refractory PTCL is currently under approval review by the EMA 
and was approved for this indication by the US FDA in June 2011 based on 
response rates investigated in two single-arm phase II studies [36-38]. 
Treatment of patients who are not transplant candidates, who fail to respond 
to second-line chemotherapy regimens, or who relapse after transplant has a 
palliative intent. Data supporting the use of most agents are limited [17]. At 
present, no single chemotherapy regimen is clearly superior to any other in 
the setting of relapsed disease. Outside the context of a clinical trial, the se-
lection of treatment should be based upon expected toxicities, patient co-
morbidities and convenience. For most patients with relapsed or refractory 
PTCL, the administration of a traditional chemotherapy regimen rather 
than the use of a novel agent is suggested. This preference is based upon the 
higher response rates seen with traditional agents and the knowledge that 
patients who achieve a complete response have a chance of long-term sur-
vival with transplantation. Novel agents are typically reserved for subse-
quent relapses [17]. 
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6 Evidence 
A literature search was conducted on January 3rd, 2012 in four databases 
(The Cochrane Library, EMBASE, Ovid, and CRD Database) yielding 28 
references overall. In addition a hand search was performed including web-
sites of the EMA and the FDA. 
Considered were only those studies which had enrolled patients with re-
lapsed or refractory HL or relapsed sALCL, resulting in two phase II single-
arm trials presented in the FDA approval documents [7, 26]. While compil-
ing this report the pivotal trial SG035-0003 for HL has been fully published 
by Younes et al. [14]. 
6.1 Efficacy and safety – pivotal studies 
Hodgkin’s lymphoma 
 
Table 6.1-1: Efficacy of the SG035-0003 trial (Hodgkin’s lymphoma) 
Study title  
A pivotal study of SGN-35 in treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) [7, 9, 
14, 39] 
Study identifier SG035-0003 trial – single arm, phase 2 trial; NCT00848926 
Single-arm, open-label, multicenter, pivotal phase II Design 
Duration  Enrolment: February 2009 – August 2009 
Median follow-up: 23.5 months [39] 
Cut-off date: primary analysis August 2010, subsequent cut-off date: 
March 2011 [7, 14] 
Hypothesis Single-arm study 
With a sample size of 100, a 29% ORR (CR +PR) would allow the Sponsor to state with 95% 
confidence (2-sided) that the true ORR is greater than 20%. Assuming the true ORR is 35%, the 
study would have approximately 90% power. 
Funding Seattle Genetics 
Intervention Brentuximab vedotin 1.8 mg/kg administered as a single IV infusion over 
30 minutes on day 1 of each 21-day cycle. Patients (pts) were allowed to 
continue on study treatment until disease progression or unacceptable 
toxicity. Pts who achieved a stable disease or better were allowed to re-
ceive a minimum of 8, but no more than 16 cycles of study treatment 
Treatment 
groups 
Control - (no control group) 
 
literature search in 4 
databases 
2 single-arm phase II 
studies included 
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Overall objective re-
sponse rate per an in-
dependent review fa-
cility (IRF) 
(primary outcome) 
ORR Sum of the complete and partial remission rates (CR and PR) 
Complete remission CR Complete disappearance of all detectable clinical evidence of 
disease. This includes lymphadenopathy, splenomegaly, hepa-
tomegaly, bone marrow involvement and disease-related symp-
toms if present before therapy. 
Partial remission PR Greater than 50% decrease in the size of the index lesions. Per 
imaging charter, index lesions are typically the largest dominant 
nodes or nodal masses, and are most representative of the pa-
tient’s disease. Up to 6 index lesions were quantitatively identi-
fied per patient. 
Stable disease SD Failure to attain CR/PR or PD, no new sites of lesions. 
Relapsed disease or 
progressive disease 
PD Any new lesion or increase by ≥50% of previously involved sites 
from nadir 
Duration of Response DOR DOR is defined as the time from start of the first documenta-
tion of ORR to the first documentation of objective tumour 
progression or to death due to any cause, whichever comes first.
Progression-free sur-
vival per IRF 
PFS Time from start of study treatment to disease progression per 
independent review group or death due to any cause. 
Endpoints and 
definitions* 
Overall survival OS Time from start of study treatment to date of death due to any 
cause. 
Results and analysis 
Analysis  
description 
Intent-to-treat analysis 
The complete remission was derived and its two-sided 95% exact confidence interval was calcu-
lated using the F distribution method (Collet 1991). 
Time-to-Event outcomes were estimated using the Kaplan-Meier methodology. 
The median duration of response, duration of response in the subset of patients achieving CR, 
PFS, OS and their two-sided 95% CI by Brookmeyer and Crowley were calculated. 
Analysis  
population 
Characteristics Demographic parameters 
102 patients from 25 sites 
Mean age, years (SD): 34 (12); 75% of patients were aged between 18-39 
years, 3 % were aged ≥65 years 
Male vs. female, n (%): 48 (47) vs. 54 (53) 
Caucasian vs. non-caucasian, n (%): 89 (87) vs. 13 (13) 
ECOG PS 0 (no symptoms) vs. 1 (symptomatic but fully ambulatory), n 
(%): 42 (41) vs. 60 (59) 
Baseline disease characteristics 
Stage I/II/III/IV (%): 4/46/26/20 
Disease stage relative to most recent prior therapy (%): Relapse: 58; Re-
fractory: 42 
Prior cancer-related therapies 
Number of systemic chemotherapy regimens (excluding ASCT), me-
dian (range): 3.5 (1 to 13) 
1 / ≥2 ASCT, n (%): 91 (89) / 11 (11) 
Time from initial diagnosis to first dose, months (range): 39.9 (11.8 to 
219.7) 
Time to relapse from ASCT, n(%) 
≤1 year: 72 (71) 
>1 year: 30 (29) 
Bone marrow involvement, n (%): 8 (8) 
B symptoms present, n (%): 35 (34) 
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Prior radiation therapy, n (%): 67 (66) 
Histology subtype, n (%): 
Nodular sclerosing: 63 (62) 
Mixed cellularity: 5 (5) 
Lymphocyte-rich: 3 (3) 
Lymphocyte-depleted: 3 (3) 
Not otherwise specified (NOS): 28 (27) 
Inclusion - Pts with relapsed or refractory HL who have received ASCT at least 12 
weeks (3 months) before first dose of brentuximab and completed any 
prior treatment with radiation, chemotherapy, biologics and/or other 
investigational agents at least 4 weeks prior to first dose of SGN-35; 
must have completed any prior immunotherapy (e.g., rituximab) or ra-
dioisotopic therapy at least 12 weeks prior first dose of SGN-35 in the 
absence of clear disease progression 
- Histologically-documented CD30-positive disease 
- Age ≥18 years OR ≥12 years enrolled at US sites 
- ECOG performance status 0 or 1 
Exclusion - Previous treatment with SGN-35 
- Previously received allogeneic HSCT 
- Congestive heart failure, Class III or IV, by the NYHA criteria 
- History of another malignancy that has not been in remission for at 
least 3 years (except: nonmelanoma skin cancer, curatively treated lo-
calized prostate cancer, and cervical carcinoma in situ) 
- Known cerebral/meningeal disease 
- Any active viral, bacterial, or fungal infection requiring treatment with 
antimicrobial therapy within two week prior to first dose of SGN-35 
- Current therapy with any other systemic anti-neoplastic or investiga-
tional agents; 
- Therapy with corticosteroids at greater than or equal to 10mg/day 
prednisone equivalent within 1 week prior to the first dose of SGN-35 
 Applicant’s endpoint results (ITT 
population) [7] 
FDA endpoint results (ITT popula-
tion) [7] 
Number of subjects n=102 n=102 
ORR, n (%; 95% CI) 
CR, n (%; 95% CI) 
PR, n (%; 95% CI) 
SD , n (%; 95% CI) 
76 (74.5; 64.9 to 82.6) 
35 (34.3; 25.2 to 44.4) 
41 (40.2; 31.5 to 49.4) 
22 (22; NA) [14] 
74 (72.5; 63.9 to 80.1) 
33 (32.4; 23.3 to 42.3) 
41 (40.2; 31.5 to 49.4) 
NA 
Median DOR, months 
(95% CI) 
ORR (n=74) 
CR (n=33) 
PR (n=40) 
NA 
 
 
6.7 (4 to 14.8) 
20.5 (12 to NE) 
3.5 (2.2 to 4.1) 
Median PFS per IRF, 
months (95% CI) 
 
5.6 (5 to 9) 
 
NA 
Descriptive 
statistics and 
estimated 
variability 
Median duration of 
OS, months (95% CI) 
 
22.4 (21.7 to NE) NA 
*responses were assessed using the 2007 Cheson response criteria [40] for malignant lymphoma. The appli-
cant defined “refractory” disease as a response of stable disease (SD) or progressive disease (PD) to the 
most recent prior therapy and “primary refractory” disease as failure to achieve CR or disease progres-
sion within 3 months of first-line therapy. Thus, the applicant’s definition of refractory in SG035-0003 
trial should not be interpreted as not responding to all lines of therapy [7]. 
Abbreviations: 95% CI – 95% confidence interval; SD – standard deviation; NE – not evaluable,  
NA – not available 
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Table 6.1-2: Incidence of most frequent (>10%) treatment-emergent adverse 
events of the SG035-0003 trial [7] 
 SG035-0003 (n=102) 
Outcome (%) Any Grade Grade 3-4 
Neutropenia 54 21 
Peripheral sensory neuropathy 52 8 
Fatigue 49 3 
Upper respiratory tract infec-
tion 
47 0 
Nausea 42 0 
Diarrhoea 36 1 
Anaemia 33 10 
Fever 29 2 
Thrombocytopenia 28 9 
Rash 27 0 
Abdominal pain 25 3 
Cough 25 0 
Vomiting 22 0 
Headache 19 0 
Arthralgia 19 0 
Pruritus 17 0 
Myalgia 17 0 
Peripheral motor neuropathy 16 4 
Constipation 16 0 
Insomnia 14 0 
Back pain 14 0 
Dyspnoea 13 1 
Alopecia 13 0 
Chills 13 0 
Night sweats 12 0 
Anxiety 11 2 
Dizziness 11 0 
Decreased appetite 11 0 
Lymphadenopathy 11 0 
Grade 
(according 
to CTC ver-
sion 3.0) 
Oropharyngeal pain 11 0 
Other Outcomes (%) 
Serious AE 25 
Treatment discontinuation due 
to: 
Completion of 16 cycles 
Progressive disease 
AEs 
Stem cell transplant 
Other 
 
 
18 
49 
21 
9 
5 
 
Grade 3/4 treatment-emergent 
AEs 
55 
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The SG035-0003 trial was the pivotal trial leading to accelerated FDA ap-
proval of brentuximab vedotin for the treatment of HL patients after failure 
of ASCT or after failure of at least two prior multi-agent chemotherapy 
regimens. Overall, 102 patients from 25 different sites with a mean age of 
34.1 (SD 12) years were included. The majority (75%) of patients was aged 
18-39 years. 71% of patients relapsed less than one year from the time of 
transplant. 66% of patients received prior radiation therapy, 35% had B 
symptoms at baseline and all patients were confirmed to have CD30-positive 
disease [7]. 
Approval is based on response rates observed in this single-arm phase II 
clinical trial. The median duration of brentuximab treatment was 27 weeks 
(range 3 to 56 weeks) with a median number of 9 (range 1 to 16) cycles ad-
ministered per patient. 75% of patients had an objective response (complete 
or partial remission) with a median duration of 6.7 months. Notably, 34% of 
patients achieved complete remission with a median duration of 20.5 
months. 
No deaths occurred within 30 days of the last dose of brentuximab vedotin; 
25 (25%) patients experienced serious adverse events (SAE); 21 (21%) pa-
tients discontinued treatment due to AEs; 56 (55%) patients had a grade 3 or 
4 treatment-emergent adverse event. The most common adverse event lead-
ing to treatment discontinuation (12 patients) and dose reduction (10 pa-
tients) was peripheral neuropathy; overall 56 patients in the SG035-0003 
trial developed neuropathy. Other SAEs included hyperglycaemia, gastroin-
testinal haemorrhage, grade 3-4 pneumonitis and pulmonary embolism [31]. 
47 protocol violations (e.g. therapy with tipifarnib 27 days prior brentuxi-
mab vedotin therapy, lower/higher dose of brentuximab vedotin, concomi-
tant medication, study conduct (e.g. missing neck CT), informed consent, 
SAE reporting) were reported in the FDA medical review.  
Sub-group analyses for ORR and CR were conducted but should be inter-
preted with caution due to the small number of patients overall which fur-
ther limits the subgroup analysis. It was shown that the treatment effects of 
brentuximab vedotin on ORR an CR were consistent for gender, age group, 
US sites, B symptoms and time to relapse post-transplant [7]. 
 
Systemic Anaplastic Large Cell Lymphoma 
 
Table 6.1-3: Efficacy of the SG035-0004 trial (systemic anaplastic large cell lymphoma) 
Study title  
A phase II study of SGN-35 in treatment of patients with relapsed or refractory systematic anaplastic 
large cell lymphoma (ALCL) [26, 41] 
Study identifier SG035-0004 trial – single arm, phase 2 trial; NCT00866047 
Single-arm, open-label, multicenter (22 sites in 5 countries: Belgium, Canada, France, 
UK, US) 
Design 
Duration  Enrolment: June 2009 to May 2010 
Maximum duration of follow-up: 17.5 months [41] 
Cut-off date for final analysis: January 14, 2011 [26] 
Hypothesis Single-arm study 
Funding Seattle Genetics 
102 HL pts from 25 sites 
OOR: 75% 
median duration of 
ORR: 6.7 months (mths) 
25% of patients suffered 
from SAEs 
 
peripheral neuropathy 
of major concern 
 
47 protocol violations 
subgroup analyses have 
to be interpreted with 
caution 
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Intervention Brentuximab vedotin, 1.8 mg/kg administered as a single IV infusion 
over 30 minutes on day 1 of each 21-day cycle. Patients (pts) were 
allowed to continue on study treatment until disease progression or 
unacceptable toxicity. Pts who achieved a stable disease or better 
were allowed to receive a minimum of 8, but no more than 16 cy-
cles of study treatment. 
Treatment 
groups 
Control - (no control group) 
Overall objective 
response rate per 
an independent re-
view facility (IRF) 
(primary outcome) 
ORR Percentage of participants who achieved a best response of 
complete remission (CR, disappearance of all evidence of dis-
ease) or partial remission (PR, regression of greater than or 
equal to 50% of measurable disease and no new sites) per 
Cheson 2007 Revised Response Criteria for Malignant Lym-
phoma [40]. 
Complete remis-
sion 
CR Percentage of participants who achieved a best response of 
CR (disappearance of all evidence of disease) per Cheson 
2007 Revised Response Criteria for Malignant Lymphoma. 
This includes lymphadenopathy, splenomegaly, hepa-
tomegaly, bone marrow involvement and disease-related 
symptoms if present before therapy. 
Partial remission PR Greater than 50% decrease in the size of the index lesions. 
Per imaging charter, index lesions are typically the largest 
dominant nodes or nodal masses, and are most representa-
tive of the patient’s disease. Up to 6 index lesions were quan-
titatively identified per patient. 
Stable disease SD Failure to attain CR/PR or PD. 
Relapsed disease or 
progressive disease 
PD Any new lesion or increase by ≥50% of previously involved 
sites from nadir. 
Duration of Re-
sponse 
DOR DOR is defined as the time from start of the first documenta-
tion of ORR to the first documentation of objective tumour 
progression or to death due to any cause, whichever comes 
first. 
Progression-free 
survival per IRF 
PFS Time from start of study treatment to disease progression 
per independent review group or death due to any cause. 
Endpoints and 
definitions 
Overall survival OS Time from start of study treatment to date of death due to 
any cause. 
Results and analysis 
Analysis  
description 
Intention-to-treat (ITT) analysis 
Characteristics - Median age, years (range): 52 (14 to 76) 
- Males vs. females, n (%): 33 (57) vs. 25 (43) 
- Caucasians, n (%): 48 (83) 
- ECOG PS 0 / 1 / 2, n (%): 19 (33) / 38 (66) / 1 (2) 
- Relapsed / refractory* disease, n (%): 29 (50) / 29 (50) 
- ALK-negative disease, n (%): 42 (72) 
- Median number of prior therapies, n (range): 2 (1 to 6) 
- Prior ASCT, n (%): 15 (26) 
- Baseline B symptoms, n (%): 17 (29) 
- Baseline bone marrow involvement, n (%): 8 (14) 
Analysis  
population 
Inclusion - Patients with relapsed or refractory ALCL who had previ-
ously received front-line chemotherapy (CHOP or multi-
agent chemotherapy regimens with curative intent) 
- Documented ALK-status 
- Histologically-confirmed CD-30 disease 
- Age ≥18 years; except in the US and Canada where patients 
≥12 years of age were enrolled 
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- previous ASCT at least 12 weeks prior to the first study dose; 
completed any treatment with radiation, chemotherapy, 
biologics and/or other investigational agents at least 4 
weeks prior to the first dose of SGN-35, unless progressing 
on therapy; completed any prior immunotherapy (e.g., 
monoclonal antibody) or radioisotopic 
- ECOG PS 0 or 1 
Exclusion - Previous treatment with SGN-35 
- Previous allogeneic transplant 
- Current diagnosis of primary cutaneous ALCL unless trans-
formed to systemic ALCL 
- Congestive heart failure, class III or IV, by the NYHA criteria 
- History of another primary malignancy that has not been in 
remission for at least 3 years; except for non-melanoma skin 
cancer, curatively localized prostate cancer, cervical carci-
noma in situ 
- Known cerebral/meningeal disease 
- Any active Grade 3 or higher viral, bacterial or fungal infec-
tion within 2 weeks prior to the first dose of SGN-35 
- Women who are pregnant or lactating 
- Patients with a known hypersensitivity to any excipient con-
tained in the drug formulation 
- Patients with dementia or an altered mental state that 
would preclude the understanding and rendering of in-
formed consent 
  
Number of subjects n=58 
ORR, n (%; 95% CI) 
CR n (%; 95% CI) 
PR n (%; 95% CI) 
50 (86; 77 to 95) 
33 (57; 44 to 70) 
17 (29; 18 to 41) 
Median DOR, months 
(95% CI) 
ORR (n=50) 
CR (n=33) 
PR (n=17) 
 
 
12.6 (5.7 to NE) 
13.2 (10.8 to NE) 
2.1 (1.3 to 5.7) 
Median PFS per IRF, 
months (95% CI) [41] 
13.3 ( 6.9 to NA ) 
Descriptive sta-
tistics and esti-
mated variabil-
ity 
Median duration of 
OS, months (95% CI) 
[41] 
NA ( 14.6 to NA) 
*Patients were defined to have refractory disease if they had a best response of PR, SD or PD if a patient had 
only one prior therapy, or best response of SD or PD to the most recent prior therapy if a patient had 
more than one prior therapy. According the applicant, patients were considered to have primary refrac-
tory disease if they had no CR or if they relapsed within 3 months of front-line therapy. As this is not a 
commonly accepted definition of refractory disease the FDA medical reviewer sought to adjudicate the 
patient’s disease status based upon more commonly accepted definitions of refractory and primary re-
fractory, yielding 11 patients with primary refractory disease; 2 with refractory to last line of treatment; 
15 had relapsed disease and the status of 1 is unknown. Factors leading to these discrepancies were 
that the applicant assigned response after extremely short periods of exposure to prior treatment regi-
mens (e.g.: in 9 cases exposure to prior lines of therapy were one cycle only), that the response of PR to 
prior therapy was not considered as a response in 5 subjects although the overall response rate in the 
applicant’s trial SG035-004 counted PR in the primary endpoint of ORR and that the response to prior 
therapies was unknown in one patient [26]. 
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Table 6.1-4: Incidence of most frequent (>10%) adverse events of the SG035-
0004 trial [26] 
Outcome (%) Any Grade Grade 3-4 
Treatment emergent adverse 
events 
100  
Blood and lymphatic system disorders 
Neutropenia 55 12 
Anaemia 52 2 
Thrombocytopenia 16 10 
Lymphadenopathy 10 - 
Nervous system disorders 
Peripheral sensory neuropathy 53 10 
Headache 16 2 
Peripheral motor neuropathy 7 3 
Dizziness 16 - 
General disorders and administrative site disorders 
Fatigue 41 4 
Pyrexia 38 2 
Chills 12 - 
Night sweats 9 - 
Pain 28 5 
Infections and infestations 
Upper respiratory tract infec-
tion 
12 - 
Gastrointestinal disorders 
Nausea 38 2 
Diarrhoea 29 3 
Abdominal pain 9 2 
Vomiting 17 3 
Constipation 19 2 
Oropharyngeal pain 9 - 
Skin and subcutaneous tissue disorders 
Rash 31 - 
Pruritus 19 - 
Alopecia 14 - 
Dry skin 10 - 
Respiratory, Thoracic and Mediastinal Disorders 
Cough 17 - 
Dyspnoea 19 2 
Musculoskeletal and Connective Tissue Disorders 
Arthralgia 9 - 
Myalgia 16 2 
Back pain 10 2 
Pain in extremity 10 4 
Muscle spasms 10 2 
Grade 
(according 
to CTC ver-
sion 3.0) 
Edema peripheral 16 - 
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Psychiatric Disorders 
Insomnia 16 - 
Anxiety 7 - 
Metabolism and Nutrition Disorders 
Decreased appetite 16 2 
Investigations 
Weight decreased 12 3 
Other Outcomes, n (%) 
Serious AE 23 (40) 
Treatment discontinuation due 
to: 
Completed 16 cycles 
Disease progression 
Adverse events 
Investigator decision 
Patient decision 
 
49 (84) 
3 (5) 
13 (22) 
14 (24) 
14 (24) 
5 (9) 
Grade 3/4 AEs 36 (62) 
 
Deaths within 30 days 6 (12) 
 
Overall 58 patients with CD30-positive disease and a median age of 52 
(range 14 to 76) years were included in the ITT analysis; 72% of patients had 
ALK-negative disease 57% of included patients were male. 33%, 66% and 
2% of patients had ECOG performance status 0, 1 and 2, respectively. All of 
the patients have received previous therapy.  
Though, 2 patients had CD30-positive disease but not ALCL (1 HL and 1 
lymphoproliferative disorder) and one patient was considered un-evaluable 
because of eligibility criteria violation and dose violation they were not in-
cluded in the ITT analysis. 3 patients completed the maximum allowable 
number of cycles of therapy (=16); 9 (16%) patients were continuing ther-
apy with brentuximab vedotin at time of data cut-off and 49 patients had 
discontinued therapy.  
The overall response rate was 86% with a median duration of 12.6 months 
and CR was achieved by 57% of patients with a median duration of CR of 
13.2 months. Having in mind, that median duration of response of PR was 
2.1 months, the duration of response appears to be driven by the patients 
who achieved complete remissions. At time of data cut-off the median PFS 
was 13.3 months (95% CI 6.9 to not available). The upper bound of the PFS 
analysis and median OS could not be estimated due to insufficient number 
of events at the time of data cut-off [41]. 
All of the subjects of the SG035-0004 trial had systemic ALCL although a 
majority (72%) had ALK-negative disease. Generally, ALK-negative disease 
is associated with a worse prognosis than ALK-positive disease. In this trial, 
a subgroup analysis showed similar response rates between the two groups 
(88% vs. 81%) [26]. 
72% of pts had ALK-
negative ALCL 
protocol violations 
ORR: 86% 
median duration of 
ORR: 12.6 months … 
… mainly driven by 
those who achieved CR 
similar response rates of 
ALK-negative and ALK-
positive ALCL 
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The most common grade 3/4 AEs were neutropenia, thrombocytopenia and 
peripheral sensory neuropathy was observed in almost half of the patients. 
Peripheral sensory neuropathy had not completely resolved by the end of 
treatment and/or long-term follow-up visits in 23 of 28 patients [26]. 40% of 
patients suffered from serious adverse events and 84% of patients discontin-
ued treatment due to several reasons. More than half of these patients dis-
continued therapy due to disease progression or adverse events. Overall the 
limitations inherent to a single-arm trial do not allow the concise attribution 
of adverse reactions to the therapy without a randomized controlled trial and 
therefore, the safety profile has not been fully characterized. 
Another issue raised in the medical review of the FDA approval documents 
is, that the applicant applied a definition of “refractory” disease that does 
not correlate with the commonly used definition. For details about the dis-
crepancy of the definition please refer to the explanation right after Table 
6.1-3. Due to these reasons each patient was “re-labelled” by the FDA based 
on the available data. Of the 29 (50%) patients having refractory disease ac-
cording to the applicant, 3 were considered to suffer from refractory disease 
by FDA’s medical reviewer; the remaining were rated as relapsed (n=15), 
primary refractory (n=11; =refractory to first-line therapy which not neces-
sarily was the previous therapy) and unknown (n=1).  
6.2 Efficacy and safety - further studies 
No further studies meeting our inclusion criteria were identified. 
7 Estimated costs 
Brentuximab vedotin is approved at a dose of 1.8mg/kg administered once 
every three weeks (= one cycle). It is available in single-use vials of 50mg. 
Thus for the treatment of a patient of 70 to 80 kg body weight three vials will 
be required. The price for nine single-use vials of 50mg brentuximab vedotin 
is EUR 30,000.- and thus one 3-week cycle of therapy for a patient with 70 to 
80 kg body weight would be EUR 10,000.-. 
According to the FDA label brentuximab vedotin is recommended for a 
maximum of 16 treatment cycles which would result in EUR 160,000.-; me-
dian duration of therapy in the two open-label single-arm phase II trials 
were 9 and 10 months, resulting in EUR 90,000.- and EUR 100,000.- esti-
mated treatment costs. 
8 On-going research 
One on-going phase III trial assessing the efficacy and safety of brentuximab 
vedotin in HL was found at ClinicalTrials.gov. No phase III trial evaluating 
brentuximab in HL was identified on the EU Clinical Trials Register; to 
most frequent grade 3/4 
AEs: neutropenia, 
thrombocytopenia and 
peripheral sensory 
neuropathy 
 
84% of pts discontinued 
therapy 
applicant’s definition of 
“refractory disease” does 
not correlate with the 
commonly used and 
accepted definition 
no further studies 
included 
one 3-week cycle of 
brentuximab treatment 
is estimated to cost 
around EUR 10,000.- 
90,000.- to 100,000.- 
for median duration of 
treatment according to 
pivotal trials 
one ongoing phase III 
trial in HL patients 
identified 
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date, no phase III trial investigating brentuximab vedotin in sALCL is regis-
tered in one of these trial registries. 
NCT01100502: The AETHERA trial is a double-blind placebo-controlled, 
randomized phase III trial investigating the efficacy and safety of brentuxi-
mab vedotin and best supportive care (BSC) compared to placebo plus BSC 
in patients with residual HL after autologous stem cell transplantation 
(ASCT). The study started in April 2010 and plans to enrol 322 patients. 
The estimated primary completion date is June 2013 and the study comple-
tion date is planned for April 2016. 
No further phase III trials evaluating brentuximab vedotin in other indica-
tions were found. Several phase II trials investigating brentuximab vedotin 
as a single agent or in combination with BSC or chemotherapy in different 
lines of therapy (e.g. first-line, in refractory patients, prior or after stem cell 
transplantation) in hematologic are ongoing. 
9 Commentary 
Brentuximab vedotin is currently not approved in Europe but Takeda has 
announced, that they submitted the marketing authorisation application in 
June 2011. In August 2011, the US FDA approved brentuximab vedotin un-
der the accelerated approval scheme for the treatment of patients with HL 
after failure of ASCT or after failure of at least two prior multi-agent chemo-
therapy regimens in patients who are not ASCT candidates and for the 
treatment of patients with sALCL after failure of at least one prior multi-
agent chemotherapy regimen [4]. 
The marketing authorisation holder initially submitted the marketing au-
thorisation application for brentuximab for relapsed and refractory HL and 
sALCL. As the definition of primary refractory disease and refractory dis-
ease to prior therapy/ies was not consistent with a widely accepted definition 
of refractory disease by the medical community, those patients initially la-
belled as “refractory”, were “re-labelled” by the US FDA’s medical reviewer 
based on the available data. Within the SG035-0003 trial 88% of patients 
classified as having refractory disease by the applicant, had a response of CR 
or PR to earlier lines of therapy and 65% of patients classified as primary re-
fractory disease had a response of CR or PR to subsequent lines of therapy. 
Only 9 of 102 patients never had a response of PR or CR to any line of ther-
apy [7]. The same discrepancy was observed in patients in the SG035-0004 
trial, where 29 (50%) patients were initially classified as having “refractory” 
disease. After re-labelling 11 patients were classified as having primary re-
fractory disease, 2 were refractory to last line of therapy, 15 had relapsed 
disease and the status of one was unknown [26]. 
comparison of 
brentuximab + BSC 
versus placebo + BSC 
brentuximab vedotin 
… not yet approved in 
Europe 
… since August 2011 
approved in the US for 
HL and sALCL 
 
 
discrepancies in the 
definition of “refractory 
disease” 
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The FDA-approval is based on two single-arm phase two studies; one study 
in patients with HL (n=102) and one in patients with sALCL (n=58). 
Originally the applicant requested regular approval for brentuximab ve-
dotin, but the FDA favoured the accelerated approval based on a recom-
mendation by the Oncologic Drugs Advisory Committee (ODAC) to require 
RCTs for regular approval and as the pivotal trial SG035-0004 was small and 
of single arm design which limited the comprehensiveness of the safety and 
efficacy analysis. Further, the accelerated approval scheme will allow access 
to brentuximab vedotin for patients who have limited treatment options for 
their rare disease in the absence of RCTs and at the same time confirmatory 
trials that could incorporate randomization which would enhance the safety 
and efficacy profiles and thus understanding of this new drug can be re-
quested [7, 26, 31]. Accelerated approval is intended for new therapies for a 
“serious or life-threatening illness” which is expected to have a meaningful 
therapeutic benefit to patients over existing treatments. The accelerated ap-
proval pathway accepts surrogate endpoints that are reasonably likely to 
predict clinical benefit. As described above, there are currently no specifi-
cally approved drugs available and there is no consistent standard of care for 
these two indications defined. Due to this unmet medical need, accelerated 
approval based on two single-arm phase II studies was granted. At the time 
of marketing authorisation, only an on-going confirmatory trial for the 
treatment of HL was registered but not for sALCL [26]. The submission of a 
study protocol by the marketing authorisation holder for a randomized 
phase III trial investigating the safety and efficacy of brentuximab in com-
bination with chemotherapy compared to chemotherapy alone in patients 
with CD30-positive T- and NK-cell lymphomas including ALCL is expected 
by December 2012 [26].  
Overall, the response rates (75% and 86% in HL and sALCL, respectively) 
in both trials were considered as clinically relevant. Complete remissions 
were achieved by 34% and 57% in HL and sALCL patients, respectively. 
Duration of ORR was 6.7 months and 12.6 months in HL and sALCL pa-
tients, respectively. Overall duration of response appears to be driven by 
those patients who achieved a complete remission as the duration of re-
sponse in these patients was 20.5 months and 13.2 months in HL and 
sALCL patients, respectively. 
Due to the single-arm design of the study neither time-to-event endpoints 
such as progression-free survival and overall survival nor observed adverse 
events can be reliably estimated [26]. A further limiting factor was the small 
sample size of both studies. Thus, efficacy evaluation in these two single-
arm trials was limited to response rates and duration of response, as these 
outcomes represent a direct treatment effect of the drug [7]. 
Also patient reported outcomes such as B symptoms (fever, night sweats, or 
unexplored weight loss) cannot be adequately evaluated in these trials be-
cause of (1) lack of validated instruments for patient reported outcomes and 
(2) the open-label nature of a single-arm trial [7].  
Overall, the small population included and the single-arm design as well as 
the endpoint of response rate do not allow to fully characterize the safety 
and efficacy profile of brentuximab vedotin based on the available data [26] 
[31]. 
FDA-approval based on 
two single-arm open-
label phase II trials with 
ORR as the primary 
efficacy endpoint 
 
 
 
accelerated approval for 
“serious or life-
threatening illness” 
 
 
currently no consistent 
standard of care 
established for HL and 
sALCL 
achieved ORR in both 
trials considered to be 
clinically relevant 
duration of ORR mainly 
driven by CR 
reliable estimates for 
time-to-event endpoints 
such as PFS and OS were 
not possible 
limited characterisation 
of safety and efficacy 
due to trial design 
 LBI-HTA | 2012 21 
The most common treatment-emergent adverse events (TEAEs), occurring 
in ≥10% of either HL or systemic ALCL patients, in the phase 2 studies are 
summarized in Table 6.1-2 for HL and in Table 6.1-4 sALCL. TEAEs occur-
ring in ≥20% of patients were peripheral sensory neuropathy (44%), fatigue 
(42%), nausea (41%), diarrhoea (34%), pyrexia (31%), upper respiratory 
tract infection (28%), neutropenia (21%), and vomiting (20%). These events 
were primarily grade 1 or 2, with the exception of neutropenia, for which 
grade 3 and Grade 4 events were reported for 13% and 7% of patients, re-
spectively. Similar patterns and incidence rates of adverse events were ob-
served for HL and systemic ALCL patients, with the exception of a higher 
incidence of upper respiratory tract infections in HL patients. In the phase 
II studies, 31% of patients had a serious adverse event (SAE), 28% had a 
SAE of Grade 3 or higher, and 15% had a SAE that was determined by the 
investigator to be related to brentuximab vedotin [9].  
Additional confirmatory trials will add important information to the safety 
and efficacy profile of brentuximab vedotin. As already mentioned above, 
the risk-benefit assessment within the accelerated approval scheme of the 
US FDA aims at balancing two important variables in granting an acceler-
ated marketing approval for brentuximab vedotin: on the one hand the new 
biological entity will be made available to patients with limited treatment 
options, and on the other hand the applicant is required to continue to col-
lect mature data on response to brentuximab and its safety profile and to 
conduct further trials to further investigate the safety and efficacy of bren-
tuximab vedotin. These confirmatory trials will be a randomized trials 
which will enhance the characterization of risk-benefit analysis [26].  
For now, there are impressive initial response rates shown for these two in-
dications that lack a definite standard of care. Patients achieving a CR bene-
fit from a median duration of response of 1 to 2 years. However, a superior 
survival rate or an improvement in quality of life has not been proven. The 
long term safety profile and the possible benefit of combining brentuximab 
vedotin with conventional chemotherapy have to be determined. Therefore, 
phase III clinical trials are mandatory and enrolment of patients in clinical 
trials is recommended. 
most frequent TEAEs: 
peripheral sensory 
neuropathy, fatigue, 
nausea, diarrhoea, 
pyrexia, upper 
respiratory tract 
infection, neutropenia 
and vomiting 
additional trials will add 
more information on 
the safety and efficacy 
profile of brentuximab 
vedotin 
despite impressive initial 
response a lot of open 
questions remain 

 LBI-HTA | 2012 23 
References 
1. National Cancer Institute. NCI Thesaurus - Brentuximab Vedotin (Code 
C66944).  05.03.2012]; Available from:  
http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI
%20Thesaurus&code=C66944. 
2. Younes, A., U. Yasothan, and P. Kirkpatrick, Brentuximab vedotin. 
Nature Reviews Drug Discovery, 2012. 11(January 2012): p. 19-20. 
3. US Food and Drug Administration. Summary Review for Regulatory 
Action - Brentuximab vedotin. 2011  05.03.2012]; Available from: 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s0
00SumR.pdf. 
4. US Food and Drug Administration. Highlights of prescribing 
information - ADCETRIS®  (brentuximab vedotin) for injection. 2011  
05.03.2012]; Available from:  
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125388s0005l
bl.pdf. 
5. Takeda Pharmaceutical Company Limited. Takeda announces EMA 
acceptance of marketing authorization application for Adcetris 
(Brentuximab vedotin). 2011  06.03.2012]; Available from:  
http://www.takeda.com/press/article_42227.html. 
6. European Medicines Agency. Public summary of opinion on orphan 
designation - Brentuximab vedotin for the treatment of cutaneous T-cell 
lymphoma (EMA/COMP/923105/2011). 2012  06.03.2012]; Available 
from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_desig
nation/2012/02/WC500121705.pdf. 
7. US Food and Drug Administration. Hodgkin Lymphoma - Medical 
Review(s) (Application number: 125388Orig1s000). 2011  20.03.2012]; 
Available from:  
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s0
00MedR.pdf. 
8. SeattleGenetics. Brentuximab vedotin (SGN-35). 2011  12.3.2012]; 
Available from:  
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetin
gMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM262593.pdf. 
9. SeattleGenetics. Brentuximab vedotin - ODAC Briefing Document - HL. 
2011  04.04.2012]; Available from:  
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetin
gMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM262593.pdf. 
10. 3. Blut und Blutbildende Organe. 3.6. Maligne hämatologische 
Erkrankungen, in Basislehrbuch Innere Medizin, H. Renz-Polster and S. 
Krautzig, Editors. 2008, Urban & Fischer: München - Jena. 
11. Furtado, M. and S. Rule, Emerging Pharmacotherapy for Relapsed or 
Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin. 
Clinical Medicine Insights: Oncology, 2012. 6: p. 31-39. 
12. Engert, A., et al., Reduced-intensity chemotherapy and PET-guided 
radiotherapy in patients with advanced stage Hodgkin's lymphoma 
(HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. 
Lancet, 2012. 379(9828): p. 1791-9. 
 
 
Horizon Scanning in Oncology 
24 LBI-HTA | 2012 
13. Mauch, P. and J. Friedberg. Long-term follow-up of the patient with 
classical Hodgkin lymphoma. 2012  03.06.2012]; Available from: 
http://www.uptodate.com/contents/long-term-follow-up-of-the-patient-
with-classical-hodgkin-
lymphoma?source=search_result&search=hodgkin+lymphoma&selecte
dTitle=11%7E150. 
14. Younes, A., et al., Results of a Pivotal Phase II Study of Brentuximab 
Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. 
J Clin Oncol, 2012. 
15. Canellos, G. and P. Mauch. Treatment of relapse of classical Hodgkin 
lymphoma after initial chemotherapy. 2012  03.06.2012]; Available from: 
http://www.uptodate.com/contents/treatment-of-relapse-of-classical-
hodgkin-lymphoma-after-initial-
chemotherapy?source=search_result&search=hodgkin+lymphoma&sele
ctedTitle=8%7E150. 
16. US Food and Drug Administration. Romidepsin. Summary Review - 
Application Number 22-393. 2009  29.2.2012]; Available from:  
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022393s000_S
umR.pdf. 
17. Jacobsen, E. and A. Freedman. Treatment of relapsed or refractory 
peripheral T-cell lymphoma. 2011  01.03.2012]; Available from: 
http://www.uptodate.com/contents/treatment-of-relapsed-or-refractory-
peripheral-t-cell-lymphoma?view=print. 
18. National Comprehensive Cancer Network. NCCN Guidelines Version 
1.2012 - Peripheral T-Cell Lymphoma 2012  20.2.2012]; Available from: 
http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. 
19. National Comprehensive Cancer Network. NCCN Clinical Practice 
Guidelines in Oncology (NCCN Guidelines(R)) - Hodgkin Lymphoma. 
Version 1.2012. 2012  27.03.2012]; Available from:  
http://www.nccn.org/professionals. 
20. Statistik Austria. Hodgkin (C81) - Krebsinzidenz (Neuerkrankungen pro 
Jahr), Österreich ab 1983. 2011  02.04.2012]; Available from:  
http://www.statistik.at/web_de/statistiken/gesundheit/krebserkrankunge
n/hodgkin/index.html. 
21. Querfeld, C., et al., Primary cutaneous and systemic anaplastic large cell 
lymphoma. ONCOLOGY, 2010. 24(7). 
22. O'Connor, O. Getting the Facts - Peripheral T-Cell Lymphoma. 2009  
02.03.2012]; Available from:  
http://www.lymphoma.org/atf/cf/%7B0363cdd6-51b5-427b-be48-
e6af871acec9%7D/PTCL09.PDF. 
23. Pro, B., S. Horwith, and J. Atmar, T-cell lymphoma: Where are we? 
Clinical Advances in Hmeatology & Oncology, 2010. 8(6): p. 
Supplement11. 
24. Dearden, C.E., et al., Guidelines for the management of mature T-cell 
and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J 
Haematol, 2011. 153(4): p. 451-85. 
25. Savage, K.J., Aggressive peripheral T-cell lymphomas (specified and 
unspecified types). Hematology Am Soc Hematol Educ Program, 2005: p. 
267-77. 
26. US Food and Drug Administration. Systemic Anaplstic Large Cell 
Lymphoma - Medical Review(s). (Application number: 
125399Orig1s000). 2011  03.04.2012]; Available from:  
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125399Orig1s0
00MedR.pdf. 
 LBI-HTA | 2012 25 
27. National Comprehensive Cancer Network. Non-Hodgkins Lymphomas - 
Version 2.2012. 2012  26.3.2012]; Available from:  
http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. 
28. Statistik Austria. Non-Hodgkin (C82-C85, C96) - Krebsinzidenz 
(Neuerkrankungen pro Jahr), Österreich ab 1983. 2011  02.04.2012]; 
Available from:  
http://www.statistik.at/web_de/statistiken/gesundheit/krebserkrankunge
n/non-hodgkin/index.html. 
29. Engert, A., D.A. Eichenauer, and M. Dreyling, Hodgkin's lymphoma: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol, 2010. 21 Suppl 5: p. v168-71. 
30. Eichenauer, D.A., A. Engert, and M. Dreyling, Hodgkin's lymphoma: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol, 2011. 22 Suppl 6: p. vi55-8. 
31. Oncologic Drugs Advisory Committee. BLA 125388 - Brentuximab 
vedotin (AdcetrisTM). 2011  05.04.2012]; Available from:  
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetin
gMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM267022.pdf. 
32. Gopal, A.K., et al., High-dose therapy and autologous stem cell 
transplantation for chemoresistant Hodgkin lymphoma: the Seattle 
experience. Cancer, 2008. 113(6): p. 1344-50. 
33. Jacobsen, E. and A. Freedman. Initial treatment of peripheral T-cell 
lymphoma. 2012  01.03.2012]; Available from: www.uptodate.com. 
34. Kewalramani, T., et al., Autologous transplantation for relapsed or 
primary refractory peripheral T-cell lymphoma. Br J Haematol, 2006. 
134(2): p. 202-7. 
35. European Medicines Agency. Refusal of the marketing authorisation for 
Folotyn (pralatrexate). 2012  03.06.2012]; Available from:  
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_
opinion_-_Initial_authorisation/human/002096/WC500125706.pdf. 
36. Freedman, A. and J. Aster. Clinical manifestations, pathologic features, 
and diganosis of peripheral T-cell lymphoma, not otherwise specified. 
2011  01.03.2012]; Available from:  
http://www.uptodate.com/contents/clinical-manifestations-pathologic-
features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-
specified?source=search_result&search=peripheral+t-
cell+lymphoma&selectedTitle=1%7E26. 
37. Coiffier, B., et al., Results From a Pivotal, Open-Label, Phase II Study of 
Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma 
After Prior Systemic Therapy. J Clin Oncol, 2012. 30(6): p. 631-6. 
38. Piekarz, R.L., et al., Phase 2 trial of romidepsin in patients with 
peripheral T-cell lymphoma. Blood, 2011. 117(22): p. 5827-5834. 
39. ClinicalTrials.gov. A pivotal open-label trial of brentuximab vedotin for 
hodgkin lymphoma. 2011  02.04.2012]; Available from:  
http://www.clinicaltrials.gov/ct2/show/results/NCT00848926?term=bren
tuximab&cond=hodgkin&phase=12&rank=6&sect=Xab876015#outco
me5. 
40. Cheson, B.D., et al., Revised response criteria for malignant lymphoma. J 
Clin Oncol, 2007. 25(5): p. 579-86. 
41. ClinicalTrials.gov. A phase 2 open-label trial of brentuximab vedotin 
(SGN-35) for systemic anaplastic large cell lymphoma. 2011  02.04.2012]; 
Available from:  
http://www.clinicaltrials.gov/ct2/show/NCT00866047?term=brentuxima
b&cond=anaplastic&phase=12&rank=2. 
